Covid RNA Vaccines: Close to 1000 Post-Vaccination Deaths


Swiss Policy Research - TRANSCEND Media Service

6 Feb 2021 – Data from vaccine adverse event reporting systems in the US (VAERS), the EU (EUDRA) and the UK (MHRA) indicates that covid RNA vaccinations have already been associated with close to 1000 deaths and several thousand non-trivial ‘adverse events’, including anaphylactic (allergic) shocks, temporary facial paralysis, and, in a few cases, birth defects. These figures may be an underestimate, as vaccine reporting systems typically cover only a fraction of adverse events.

For the US, see: 501 Deaths + 10,748 Other Injuries Reported Following COVID Vaccine

Compared to the tens of millions of covid RNA vaccinations already performed, these numbers are small. Compared to the amount of covid deaths, these numbers are small, too. But compared to the standards for safe medical products, these numbers are certainly significant. Moreover, little is still known about the long-term safety profile of experimental RNA vaccines. Back in 2009/2010, it took one year for the public to learn about neurological damages caused by swine flu vaccine adjuvants.

In terms of RNA vaccine effectiveness, data from vaccination leader Israel indicates that the risk of infection and hospitalization is indeed much lower in senior citizens having received the second vaccine dose (92% relative effectiveness), but the overall test positivity rate in the population has yet to decrease, and the first vaccine dose is clearly insufficient to prevent infection in senior citizens.

Data sources: Reporting sytems OpenVAERS (USA), EUDRA (EU), MHRA (UK).

See also: Anti-Vaxxers Misuse Federal Data to Falsely Claim COVID Vaccines Are Dangerous (Vice)

Related: Vaccines: Successes and Controversies (15 documentaries)

See also


Swiss Policy Research, founded in 2016, is an independent, nonpartisan and nonprofit research group investigating geopolitical propaganda in Swiss and international media. SPR is composed of independent academics that for personal and professional reasons prefer to protect their identities, and receives no external funding; there are no financial sponsors or backers. Our articles have been published or shared by numerous independent media outlets and journalists, among them Julian Assange, and have been translated into more than two dozen languages.

Go to Original –

Tags: , , , , , , , , , , , , , , , , ,

Share this article:

DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.

Comments are closed.